Roberts Brandi
Chief Financial Officer
Roberts Brandi has filed 4 SEC Form 4 filings (4 transaction rows) across 1 company, with disclosures dating back to 2026. 4 of those filings fall inside the rolling window. Most recent filing: Aug 12, 2026.
On the most recent filing, Roberts Brandi is listed as Chief Financial Officer at Definium Therapeutics, Inc. Inside the rolling window, Roberts Brandi reported no open-market purchases and 1 open-market sale totaling $136K in DFTX.
Companies traded
Other insiders at DFTX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$136K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Roberts Brandi made?
Roberts Brandi has filed 4 SEC Form 4 filings (4 transaction rows) across 1 company since 2026.
Which companies does Roberts Brandi trade?
Roberts Brandi has filed SEC Form 4 disclosures for 1 company, including DFTX.
When was Roberts Brandi's most recent SEC Form 4 filing?
Roberts Brandi's most recent SEC Form 4 filing on Tracefour is dated Aug 12, 2026.
What is Roberts Brandi's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Roberts Brandi is listed as Chief Financial Officer.
What is Roberts Brandi's total buy and sell value in the current window?
Inside the rolling retention window, Roberts Brandi bought $0 and sold $136K based on SEC Form 4 filings.
What was Roberts Brandi's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 3,013 DFTX shares on 2026-06-25, worth $136K, per SEC Form 4 filings.